Imaging Neural Correlates of Ketamine Using PET/MR
- Conditions
- Major Depressive Disorder
- Interventions
- Registration Number
- NCT04587778
- Lead Sponsor
- Medical University of Vienna
- Brief Summary
The purpose of this randomized, placebo-controlled study is to investigate pharmacodynamic differences between racemic ketamine and esketamine using functional fluorodeoxyglucose (\[18F\]FDG) positron emission tomography/magnetic resonance imaging (PET/MR)
Pilot study I:
A pilot study with healthy controls will be performed in order to investigate pharmacokinetic behavior and acute behavioral effects of intravenous ketamine infusion.
Pilot study II:
A pilot study including 15 healthy volunteers will be performed in order to optimize scanning procedures. The pilot study follows a randomized, placebo-controlled, double-blind, cross-over study design. After enrollment into the study all subjects will undergo two \[18F\]FDG PET/CT scans in the course of which they will receive either S-ketamine or placebo during the first scan and the respective other study medication during the second scan.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 65
- General health based on medical history, physical examination and structured clinical interview for the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) (SCID)
- Age 18 to 55 years
- Right-handedness (due to potential lateralization effects of lefthanded subjects)
- Willingness and competence to sign the informed consent form.
- Current or history of psychiatric or neurological disease
- Current medical illness requiring treatment
- Pregnancy or current breastfeeding
- Current or former substance abuse
- Diagnosis of an Axis-1 psychotic disorder in a first-degree relative
- Any contraindication for MRI (e.g., MR incompatible implants, etc.) including dental implants causing signal artifacts
- For subjects participating in earlier studies using ionizing radiation, the total radiation exposure of 30 millisievert (mSv) over the last 10 years must not be exceeded, as specified in the Austrian legislation on radiation protection (www.ris.bka.gv.at). Accordingly, body weight >100kg is an exclusion criterion (5.1 Megabequerel (MBq)/kg * 100kg * 0.019 mSv/MBq* 0.885 = 8.58 mSv per scan, the factor 0.885 is considered due to continuous radioligand infusion, see PET scanning).
- Failure to comply with the study protocol or to follow the instruction of the investigating team.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description Esketamine ((S)-Ketamine) Placebo Single-blind placebo (saline) infusion will be performed during the first PET/MR scan in all subjects, i.e. both arms. In a cross-over study design, esketamine will be administered during the second scan and racemic ketamine during the third scan. Racemic ketamine ((R,S)-Ketamine) Placebo Single-blind placebo (saline) infusion will be performed during the first PET/MR scan in all subjects, i.e. both arms. In a cross-over study design, racemic ketamine will be administered during the second scan and esketamine during the third scan. Esketamine ((S)-Ketamine) Ketamine Hydrochloride Single-blind placebo (saline) infusion will be performed during the first PET/MR scan in all subjects, i.e. both arms. In a cross-over study design, esketamine will be administered during the second scan and racemic ketamine during the third scan. Racemic ketamine ((R,S)-Ketamine) Esketamine Single-blind placebo (saline) infusion will be performed during the first PET/MR scan in all subjects, i.e. both arms. In a cross-over study design, racemic ketamine will be administered during the second scan and esketamine during the third scan. Esketamine ((S)-Ketamine) Esketamine Single-blind placebo (saline) infusion will be performed during the first PET/MR scan in all subjects, i.e. both arms. In a cross-over study design, esketamine will be administered during the second scan and racemic ketamine during the third scan. Racemic ketamine ((R,S)-Ketamine) Ketamine Hydrochloride Single-blind placebo (saline) infusion will be performed during the first PET/MR scan in all subjects, i.e. both arms. In a cross-over study design, racemic ketamine will be administered during the second scan and esketamine during the third scan.
- Primary Outcome Measures
Name Time Method Change in cerebral blood flow (CBF) during PETMR/during 45 minutes of infusion Change in CMRGlu between each PET/MR scan
Change in Cerebral metabolic rate of glucose (CMRGlu) during PETMR/during 45 minutes of infusion Change in CMRGlu between each PET/MR scan
- Secondary Outcome Measures
Name Time Method Change in Positive and Negative Syndrome Scale one hour after infusion to baseline Minimum: 30, Maximum: 210; higher score indicates worse outcome
Change in Brief Psychiatric Rating Scale one hour after infusion to baseline Minimum: 18, Maximum: 126; higher score indicates worse outcome
Change in Clinician Administered Dissociative States Scale one hour after infusion to baseline Minimum: 0, Maximum: 92; higher score indicates worse outcome
Trial Locations
- Locations (1)
Medical University of Vienna
🇦🇹Vienna, Austria